Lung Cancer

LungA Phase 2, Open-label, Multicenter Study of IBI363 (PD1-IL2m) in Subjects with Advanced Solid Malignancies
Colon, Esophagus, Larynx, Lip, Oral Cavity and Pharynx, Lung, Other Digestive Organ, Pancreas, Phase I, Rectum, Small Intestine, StomachA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
LungA Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody-Drug Conjugate (ADC), Compared to Investigator's Choice Therapy in Participants With Relapsed Small Cell Lung Cancer
Anus, Esophagus, Lip, Oral Cavity and Pharynx, Lung, Other Female Genital, Other Male Genital, Other Urinary, Phase I, Urinary BladderA Phase 1 Dose-Escalation and Expansion Study Evaluating the Safety, Efficacy, and Pharmacokinetics of EVOLVE104 in Subjects With Advanced Urothelial and Squamous Cell Carcinomas
Breast, Lung, Ovary, Phase IA Phase 1, Multicentre, Open-label, Multiple-dose Study to Determine Safety, Tolerability, and Preliminary Efficacy of SBO-154 in Subjects With Advanced Solid Tumors